BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 12429797)

  • 1. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
    Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
    Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
    Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
    Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis.
    Iguchi T; Aishima S; Taketomi A; Nishihara Y; Fujita N; Sanefuji K; Sugimachi K; Yamashita Y; Maehara Y; Tsuneyoshi M
    Hum Pathol; 2009 Feb; 40(2):174-80. PubMed ID: 18835624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.
    Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
    Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma.
    Su MC; Hsu C; Kao HL; Jeng YM
    Cancer Lett; 2006 Apr; 235(1):34-9. PubMed ID: 16125303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Three deceptive cases of intrahepatic metastases of colorectal origin with endobiliary growth, simulating cholangiocarcinoma. Importance of immunostaining of cytokeratin 7 and 20].
    Rullier A; Le Bail B; Rullier E; Lamouliatte H; Saric J; Bioulac-Sage P
    Ann Pathol; 1999 Mar; 19(1):33-6. PubMed ID: 10320910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
    Chiu CT; Chiang JM; Yeh TS; Tseng JH; Chen TC; Jan YY; Chen MF
    Dig Liver Dis; 2008 Sep; 40(9):749-54. PubMed ID: 18329969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma.
    Park BK; Paik YH; Park JY; Park KH; Bang S; Park SW; Chung JB; Park YN; Song SY
    Am J Clin Oncol; 2006 Apr; 29(2):138-42. PubMed ID: 16601431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors).
    Schmitz KJ; Lang H; Kaiser G; Wohlschlaeger J; Sotiropoulos GC; Baba HA; Jasani B; Schmid KW
    Hum Pathol; 2009 Dec; 40(12):1706-14. PubMed ID: 19683330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes.
    Hirohashi K; Uenishi T; Kubo S; Yamamoto T; Tanaka H; Shuto T; Kinoshita H
    Hepatogastroenterology; 2002; 49(44):326-9. PubMed ID: 11995443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type.
    Shibahara H; Tamada S; Higashi M; Goto M; Batra SK; Hollingsworth MA; Imai K; Yonezawa S
    Hepatology; 2004 Jan; 39(1):220-9. PubMed ID: 14752841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
    Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
    Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type.
    Aishima S; Kuroda Y; Nishihara Y; Iguchi T; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
    Am J Surg Pathol; 2007 Jul; 31(7):1059-67. PubMed ID: 17592273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
    Okamura N; Yoshida M; Shibuya A; Sugiura H; Okayasu I; Ohbu M
    Pathol Int; 2005 Nov; 55(11):724-31. PubMed ID: 16271085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
    Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
    Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
    Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
    Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker.
    Tanaka S; Hirohashi K; Uenishi T; Yamamoto T; Hamba H; Kubo S; Tanaka H; Shuto T; Ogawa M; Kinoshita H
    Hepatogastroenterology; 2004; 51(57):839-41. PubMed ID: 15143930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary liver cancer with dual expression of hepatocyte and bile duct epithelial markers.
    Uenishi T; Hirohashi K; Shuto T; Tsukamoto T; Yamamoto T; Ogawa M; Kubo S; Tanaka H; Kinoshita H
    Hepatogastroenterology; 2002; 49(46):1092-4. PubMed ID: 12143210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.